ストックスクリーナーアプリを入手
1.17
4.46%
0.05
前日終値:
$1.12
開ける：
$1.12
24時間の取引高:
80,415
Relative Volume:
0.29
時価総額：
$2.62M
収益：
$6.59M
当期純損益:
$-18.12M
株価収益率:
-0.1237
EPS:
-9.4605
ネットキャッシュフロー:
$-11.45M
1週間 パフォーマンス:
-5.65%
1か月 パフォーマンス:
-29.52%
6か月 パフォーマンス:
-52.36%
1年 パフォーマンス:
-95.00%
1日の値動き範囲:
$1.09
$1.1908
1週間の範囲:
$1.09
$1.34
52週間の値動き範囲:
$1.09
$24.42
Hcw Biologics Inc Stock (HCWB) Company Profile
Compare HCWB vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
1.17 | 2.62M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Hcw Biologics Inc (HCWB) 最新ニュース
HCW Biologics Announces Special Meeting for Stockholder Vote on Warrant Issuance Linked to July 2026 Private Placement - Kalkine Media
HCW Biologics Announces Strategic $1.5 Million Financing - TipRanks
HCW Biologics Prices $1.5 Million Private Placement With Existing Stockholder - Quiver Quantitative
HCW Biologics Announces Pricing of $1.5 Million Private Placement - GlobeNewswire
Clinical trials and drug studies are among the planned uses for proceeds from HCW Biologics' $1.5 million deal. - Stock Titan
HCW Biologics Board Withdraws Performance Equity Plan Proposal After Stockholder Feedback - minichart.com.sg
HCW Biologics Updates Special Meeting Proxy Materials - TipRanks
HCW Biologics removes equity-plan proposal, reschedules special meeting - TradingView
HCW Biologics (HCWB) asks holders to lift warrant share cap - Stock Titan
HCWB Looks 92.8% Undervalued on GF Value™ Despite Financial Dist - GuruFocus
HCW Biologics signs global HCW11-006 distribution deal - TipRanks
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent - Yahoo Finance
HCW Biologics signs distribution deal with Akron Biotech By Investing.com - Investing.com Canada
HCW Biologics signs distribution deal with Akron Biotech By Investing.com - Investing.com India
HCWB Stock In Focus As Holders File To Sell 1.24M Shares - timothysykes.com
HCWB Stock Faces Pressure As Shareholders Plan Secondary Sale - stockstotrade.com
HCW Biologics signs distribution deal with Akron Biotech - Investing.com
HCW Biologics Enters Exclusive Distribution Agreement with Akron Biotech for HCW11-006 Reagent Commercialization - Quiver Quantitative
A reagent may help make longer-lasting immune cells. HCW Biologics will supply it to Akron. - Stock Titan
Hcw Biologics Stock Price Forecast. Should You Buy HCWB? - StockInvest.us
HCW Biologics (NASDAQ: HCWB) asks investors to vote on more equity than its current share count - Stock Titan
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - Investing News Network
HCWB Looks 90.0% Undervalued on GF Value™ - GuruFocus
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - The Manila Times
HCW Biologics Strengthens U.S. Patent Estate for Its Lead - GlobeNewswire
HCW Biologics Inc. SEC Filing (Sep 1, 2026) - Stock Titan
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceBackspread Trade - siam.in
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceInstitutional Flow Picks - dars.gov.et
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Canada
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Nigeria
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com India
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com UK
Human studies showed HCW Biologics’ fusion expanded progenitor T cells and natural killer cells - Stock Titan
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com
HCW (HCWB) Financial Update: The EPS Result Is Above Expectation in the Latest Reading; Investor Response: The Share Price Adds 2.83% on the DayEarnings Call Transcript - vinanet.vn
HCW (HCWB): Finishes 2.83% Up at $2.18 in the Latest Reading; Range Check: Price Remains Between $2.07 Support and $2.29 ResistanceBPI Bull Confirmed - vinanet.vn
HCW Biologics (NASDAQ: HCWB) registers PIPE, warrant shares - Stock Titan
581,047 Common Stock of HCW Biologics Inc. are subject to a Lock-Up Agreement Ending on 20-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
HCWB Q1 2026 Earnings: EPS of $2.22 Smashes Consensus by 182.44% Despite No RevenueHigh Estimate Range - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusDividend Arbitrage - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusInvestment Factor - dars.gov.et
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results - The Manila Times
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusBollinger Squeeze - dars.gov.et
HCW Biologics regains Nasdaq bid price compliance - scanx.trade
HCW Biologics requests FDA meeting for HCW11-018b solid tumor candidate - scanx.trade
HCW Biologics Q2 net loss widens to $5.2M despite revenue surge - scanx.trade
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Nigeria
HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary - TradingView
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Australia
Hcw Biologics Inc (HCWB) 財務データ
収益
当期純利益
現金流量
EPS
Hcw Biologics Inc (HCWB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Flowers Lee | SVP of Business Development |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
8,691 |
| GARRETT SCOTT T | Director |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
41,644 |
| Wong Hing C | Chief Executive Officer |
May 22 '26 |
Buy |
1.41 |
113,879 |
160,000 |
615,790 |
| GARRETT SCOTT T | Director |
May 22 '26 |
Buy |
1.41 |
177,936 |
250,000 |
203,441 |
| Byam Rebecca | Chief Financial Officer |
May 22 '26 |
Buy |
1.41 |
14,235 |
20,000 |
57,245 |
3.09%
0.72%
大文字化:
|
ボリューム (24 時間):